accurate.easy.comfortable.
Transcription
accurate.easy.comfortable. Bringing more to the table. accurate.easy.comfortable. stereotactic biopsy table Mammotome MammoTest™ Features -120° 94cm (37in) 88cm (34.6in) 72cm (28.3in) 28cm (11in) +120° •ergonomic table with large central breast aperture (measuring 11 inches) •fully digital detector uses CCD with 1024 x 1024 pixels •detector resolution: 10 lp/mm •spot field of view: 50 x 50 mm •Target on Scout for exact needle positioning •true 360 degree access without moving the patient 183cm (72in) 198cm (78 in) •lateral arm for close needle access to lesion •unique table design minimises patient repositioning •PACS and DICOM- compatible for high connectivity and increased workflow efficiency proven performance Mammotome MammoTest™ for a precise and efficient diagnosis. We know how challenging a breast biopsy can be for both you and your patient. This is why we have integrated Mammotome MammoTest™— a fully digital prone biopsy table— into our portfolio of comprehensive breast care solutions. Mammotome MammoTest™ is designed with maximum access and targeting, as well as utmost patient and user comfort. accurate. easy. comfortable. The Mammotome MammoTest™ table brings optimised access through: An optimised and minimised number of procedural steps make the procedure intuitive, efficient and patient friendly. A wide range of gantry movement avoids patient repositioning. With Mammotome MammoTest™, the patient always rests in a more comfortable prone position. The Mammotome MammoTest™ ensures that the whole procedure is kept out of your patient’s view, while allowing for easy eye contact and conversation. Further ergonomic features reduce shoulder and back stress. All this helps to minimise patient stress and provides: •angled targeting via polar coordinates •all-angles 360 degree access •Target on Scout option •lateral arm option •arm-through-hole technique Bringing more to the table. Together, Mammotome MammoTest™, Mammotome revolve® and Mammotome CoreVision® provide an integrated approach to redefining procedural efficiency without compromising tissue quality – from positioning to diagnosis. Mammotome revolve® offers the latest advancements in VAB technology, designed for accuracy and unparalleled efficiency while staying true to your core purpose – acquiring high quality tissue during your patient’s biopsy. Mammotome CoreVision® verifies the presence of micro-calcifications in core biopsies, rapidly confirming a successful biopsy procedure right in the stereotactic suite. •utmost patient comfort •efficiency and comfort for the user for more information Please contact your Mammotome representative. +PHONE: 0800 862 0587 +FAX: 0800 862 0585 +EMAIL: [email protected] +WEB: www.mammotome.com + ADDRESS: DEVICOR Medical UK Ltd., 20-22 Bedford Row, London, WC1R 4JS, United Kingdom +INFORMATION FOR EUROPEAN COUNTRIES OUTSIDE OF THE UK BY: DEVICOR Medical Germany GmbH • Südportal 5 • D-22848 Norderstedt, Germany Phone: +49 (0) 40-59 35 59 10 • Fax: +49 (0) 40-500 98 940 Email: [email protected] • www.mammotome.com ©2014 Devicor® Medical Products, Inc. All rights reserved. For complete product details, see Instructions for Use. MDM 14-0022 Rev 06/14
Similar documents
MammoTest Brochure
both you and your patient. This is why we have integrated Mammotome MammoTest™ — a fully digital prone biopsy table — into our portfolio of comprehensive breast care solutions. Mammotome MammoTest™...
More informationexperienced. focused. evolving. just like you.
+ Phone: Contact your Mammotome Customer Service Representative at 1-877-9-A-MAMMO between the hours of 8:30am and 6:30pm est. Shipping details and an order confirmation number will be provided to...
More informationLiquid Biopsy Market Revenue, Opportunity, Forecast and Value Chain 2016-2026
Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies. Liquid biopsy helps in collection of a wide range of information about a cancer/tumor through a simple blood sample. The procedure can help in exact detection of mutations in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC). Furthermore, identification of traces of the cancer’s DNA in the blood could help in administration of precision treatments that could increase the probability of treatment effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally invasive method can be performed with 5 milliliters of blood which would detect present state of metastases in various tumors. The liquid biopsy process is witnessing increasing adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is expected to emerge as a game changer in the field of oncology in the forthcoming years.
More information